Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!


















Authors
 

ABBOTT INDIA Fact Sheet, ABBOTT INDIA Financial Results - Equitymaster

Jan 29, 2022 | Updated on Jan 29, 2022

Check out ABBOTT INDIA fact sheet and ABBOTT INDIA financial results online at Equitymaster.

ABBOTT INDIA Quarterly Results - Equitymaster

Jan 28, 2022 | Updated on Jan 28, 2022

Check out latest ABBOTT INDIA Quarterly Results online at Equitymaster.

ABBOTT INDIA Share price, NSE/BSE Forecast News and Quotes| Equitymaster

Jan 28, 2022 | Updated on Jan 28, 2022

ABBOTT INDIA: Get the latest ABBOTT INDIA Share price and stock price updates, live NSE/BSE share price, share market reports, financial report, balance sheet, price charts, financial forecast news and quotes only at Equitymaster.com.

Abbott India: DPCO blues

Jul 22, 2003

Following the worldwide sale of BASF AG’s (Knoll’s parent company) pharmaceutical business to Abbot Laboratories in Dec ’00, Knoll Pharma had become a subsidiary of BASF AG. Consequently, Knoll Pharma was renamed as Abbott India Ltd (AIL) with effect from July ’02. Abbot Laboratories is a global healthcare company devoted to discovery, development, manufacture and marketing of pharmaceuticals, nutritional and medical products including devices and diagnostics. The merger is expected to increase

Knoll Pharma:1QFY03 net up 53%

Jul 2, 2002

Knoll Pharmaceuticals, (now a subsidiary of Abott Labs) has registered marginal decline in sales for 1QFY03. However, a sharp rise in operating margins helped the company register a 53% rise in profits. Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market.

Knoll Pharma: Buyback on hold

Jun 18, 2002

Knoll Pharmaceuticals, (now a subsidiary of Abott Labs) has registered a marginal decline in sales for 1QFY03. However, a sharp rise in operating margins helped the company register a 53% rise in profits. Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market.

Knoll Pharma: Consolidating operations

Mar 4, 2002

Knoll Pharma has declared a 33% drop in net profits for the year ended November'01. The company has changed its accounting year from December to November year ending. Hence the latest results are not strictly comparable as this year of the company was for a period of 11 months.

Knoll Pharma: Mounting competition

Dec 28, 2001

Following the worldwide merger of Knoll AG and Abbott Inc, Knoll Pharma, is now a subsidiary of Abbott Inc. Though the company remains the leader in the domestic insulin business, it is facing severe heat of competition from domestic players. One would expect that the product basket of the company could receive a boost with new parent in place. However, unless this happens the company would face stiff domestic competition.

Knoll Pharma: 3QFY02 PBT rise 26%

Oct 23, 2001

Knoll Pharmaceuticals, subsidiary of Abbot AG, has declared its 3QFY02 report card. While sales have grown by around 3%, operating margins have jumped 240 basis points. Higher operating margins, coupled with interest savings helped to achieve a 26% growth in PBT. However, net profit dropped by 48% due to inclusion of an extraordinary income to the tune of Rs 132 m in the last year from sale of property at Sion, Mumbai. Similarly the first half also had an extra-ordinary income of Rs 161 m on ac

Knoll Pharma: An update

Aug 29, 2001

Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market with around 55% market share in the insulin business. However, most of the company's drugs are under DPCO coverage. The company’s financials went through a bumpy ride in the last six months due to two important price changes ordered by DPCO.

Knoll Pharma: PBT rises 29% in 1HFY02

Jul 16, 2001

Knoll Pharmaceuticals, formerly Indian subsidiary of Knoll AG, has declared excellent performance for first half of FY02 in line with our expectation (Insert Link to Knoll Pharma Article dated 30th April'01: Better days ahead). Apparently, net profit has dropped by 27% due to inclusion of an extraordinary income to the tune of Rs 161 m in the last year from sale of mutual fund units. The performance in second quarter is remarkable considering that there was a drop in operating profit in the firs

Knoll Pharma open offer: Pros and cons

May 7, 2001

Abbott Laboratories Inc has made an open offer to the shareholders of Knoll Pharma to acquire 20% of the company’s equity at Rs 328 per share. This follows Knoll Pharma’s parent company’s sell-out to Abbott Inc. Is it worth for Knoll Pharma shareholders to consider this option?

Knoll Pharma: Better days ahead

Apr 30, 2001

Knoll Pharmaceuticals, (formerly Indian subsidiary of Knoll AG) has declared a drop in net profit for 1QFY02 by 23%. Knoll Pharma is the leading player in the domestic insulin, anti-diabetic, pain control, antacid market. The drop in net profit was in line with our expectations following a cut in Ibuprofen prices by NPPA in January this year. Ibuprofen is a bulk drug which is used in pain management segment. As Knoll Pharma is a market leader in Ibuprofen market, the price cut had a severe impac

Knoll Pharma: Other income buoys net

Feb 23, 2001

Knoll Pharma has reported a 5% jump in the net profit on the back of a 14.3% jump in the turnover. Even last year the company derived a substantial portion of its revenues from other income. Thus on a like to like basis, the profit growth has been an impressive 55%, if one were to exclude the non–recurring other income in both the years after adjusting the tax paid on that.

Abbott–Knoll merger: The Indian synopsis

Dec 18, 2000

Abbott Inc announced the takeover of Knoll Pharma, the pharmaceutical arm of the German conglomerate BASF on Saturday. We take a look at the operations of both these companies in India.

Knoll Pharma: A strong dose

Jul 29, 2000

A 30% growth in earnings on a 13.6% growth in the topline is a strong enough dose but Knoll has during the quarter also sold units of mutual funds which have realised an extraordinary profit of Rs 160.5 m.

Knoll Pharma: The anti-diabetes king consolidates

Jul 4, 2000

Knoll Pharmaceuticals is the Indian subsidiary of Knoll AG, which in turn is part of the health and nutrition division of BASF AG. Knoll is a leading player in the Indian insulin, pain control and antacid market with brands such as Brufen (anti–rheumatic), Digene (antacid), Epilex (anti–epilepsy) and Cremmafin (laxative).

Knoll, Abbott likely to be affected by NPPA decision

Feb 14, 2000

The prices of formulations using ibuprofen and erythromycin are likely to be reduced. The price rise is expected to be in the range of around 20%.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS